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Abstract
Cystinuria is an incompletely dominant disorder characterized by defective urinary cystine 
reabsorption that results in the formation of cystine-based urinary stones. Current treatment 
options are limited in their effectiveness at preventing stone recurrence and often poorly tolerated. 
We report that the nutritional supplement α-lipoic acid inhibits cystine stone formation in the 
Slc3a1-/- mouse model of cystinuria by increasing the solubility of urinary cystine. These findings 
identify a novel therapeutic strategy for the clinical treatment of cystinuria.
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Kidney stones affect approximately 9% of the U.S. population, with the rate of incidence 
and prevalence increasing within the U.S. and globally1. While surgical techniques to 
remove obstructive stones have improved, few therapeutic advances have been made to 
prevent stone recurrence2. Cystinuria is a rare type of kidney stone disease caused by 
mutations in the SLC3A1 and/or SLC7A9 genes that are responsible for cystine reabsorption 
in the renal proximal tubule, and is characterized by aggressive and recurrent cystine stone 
formation. Currently available interventions aimed at preventing cystine stones in these 
individuals include increasing fluid intake and pharmaceutical compounds that increase 
urinary pH or interfere with cysteine dimerization3. However, these measures have marginal 
effects on stone prevention, and the medications are poorly tolerated with sometimes serious 
adverse side effects4,5. Furthermore, cystine stones are dense, large, and largely resistant to 
extracorporeal shock wave lithotripsy (SWL), often requiring multiple procedures or surgery 
to remove obstructive stones6. The high rate of stone recurrence and surgical burden 
associated with cystinuria thus places these patients at increased risk for reduced kidney 
function and chronic kidney damage7.
To address the clinical challenges associated with cystinuria, we utilized the Slc3a1-/- mouse 
model which develops cystine urolithiasis, to identify compounds that effectively inhibit 
stone formation8. Micro-computed tomography (μCT) analysis revealed that Slc3a1-/- mice 
accumulated urinary bladder stones at an average rate of 1 mm3/day (Fig. 1a). We applied 
this measure to evaluate compounds for their effects on cystine stone growth in vivo. 
Notably, treatment of mice with the drug tiopronin, a sulfhydryl drug approved for treatment 
of cystinuria, had no significant effect on cystine stone growth rate compared to mice on a 
regular diet (Supplementary Fig.1a). This result was consistent with observations that 
tiopronin has limited therapeutic effect9. Similarly, treatment of mice with L-cystine 
dimethylester (L-CDME), a cystine crystal growth inhibitor that has previously been shown 
to result in smaller stone size distrubtion8,10, also had no significant effect on cystine stone 
growth rate compared to mice on a regular diet (Supplementary Fig. 1b). To identify more 
effective inhibitors, we evaluated compounds for cystine stone inhibition based on two 
criteria: activation of the antioxidant response signaling pathway that promotes glutathione 
synthesis and cellular cystine uptake, and successful in vivo delivery to the renal proximal 
tubules and urine. Treatment with the pro-antioxidant sulforaphane11 had a modest effect on 
cystine stone growth (Supplementary Fig. 1c). In contrast, we found that the pro-antioxidant 
compound α-lipoic acid (α-LA) was a strong suppressor of stone growth as mice treated 
with α-LA had lower stone formation growth compared to untreated mice (Fig. 1b).
We treated 4 to 7-week old male Slc3a1-/- mice, prior to any stone formation, with oral 
administration of α-LA (0.5%) supplementation into the diet. While all untreated Slc3a1-/- 
mice developed stones within 6 weeks of the study and continued to progressively accrue 
stone volume, mice treated with α-LA had significantly delayed stone formation, lower 
overall stone volume accumulation, and formed fewer stones (Fig. 1c and Supplementary 
Fig. 1d-e). Further, α-LA was an effective suppressor of cystine stone growth, as Slc3a1-/- 
mice with existing stones demonstrated decreased stone growth rate when treated with α-
LA. Withdrawal of α-LA over a period of four weeks resulted in reversion of stone growth 
rate to the initial rate of growth (Fig. 1d), suggesting that continuous α-LA treatment was 
necessary for its effect on stone inhibition.
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Mouse intake of the 0.5% α-LA supplemented diet is approximately equivalent to a human 
dose of 2700 mg/day for a 67 kg adult12. While no human toxicity limit for α-LA 
supplementation has been established, we tested whether lower doses of α-LA effectively 
inhibited stone growth in the Slc3a1-/- mouse. 0.1% and 0.25% α-LA in the diet, 
approximately equivalent to human doses of 540 and 1350 mg/day respectively12, 
significantly attenuated cystine stone growth compared to untreated mice (Fig. 1e). 
However, these moderate doses were also significantly less effective than the high dose of 
0.5% α-LA in the diet, indicating that the effect of α-LA on cystine stone growth was dose-
dependent (Fig. 1e). Of note, clinical trials assessing α-LA daily treatment at 600 mg to 
1800 mg doses have reported no major adverse reactions13.
α-LA treatment protected Slc3a1-/- kidneys from atrophy and hydronephrosis-related 
damage (Supplementary Fig. 2)14, likely through the prevention of obstructive stones. 
Slc3a1-/- mice treated with α-LA had normal body weight, and modestly greater food intake 
and water intake compared to mice not treated with α-LA (Supplementary Fig. 3a-c), 
suggesting that α-LA did not prevent stones through an anorexic mechanism15 or by 
promoting hydration. Additionally, urinary pH was not significantly different between mice 
treated with α-LA compared to untreated controls (Supplementary Fig. 3d).
α-LA treatment did not affect urinary cystine concentration in Slc3a1-/- mice, as cystine 
levels in control versus α-LA treated mice were not significantly changed (Fig. 2a). This 
result suggests that α-LA (or its reduced form dihydrolipoic acid) did not chelate cysteine or 
interfere with cysteine dimerization, as is the mechanism of thiol binding drugs like 
tiopronin and penicillamine.
We then tested the hypothesis that α-LA inhibited cystine stone formation by promoting 
cystine transport and metabolism. α-LA treatment has been shown to increase Nrf2 nuclear 
localization and the transcription of Nrf2-mediated genes that promote glutathione 
biosynthesis via cystine import and cellular cysteine utilization16,17. We examined whether 
α-LA effects on cystine stone growth were dependent upon Nrf2 in vivo. Slc3a1-/-; Nrf2-/- 
double knockout mice were treated with α-LA and compared to Slc3a1-/- control littermates. 
Nrf2 did not contribute to cystine stone formation, as the rate of stone growth in Slc3a1-/-; 
Nrf2-/- mice was not significantly different compared to Slc3a1-/- mice (Fig. 2b). 
Additionally, the effect of α-LA on stone growth was conserved in the Slc3a1-/-; Nrf2-/- 
mice, indicating that α-LA regulated cystine stone formation independently of its role in 
activating the Nrf2-dependent antioxidant response (Fig. 2b).
Based on these results and the clinical observations that α-LA administration alters urine 
attributes18, we examined whether α-LA affected cystine solubility in the urine. Ex vivo 
cystine precipitation analysis revealed that cystine was considerably more soluble in α-LA 
treated urine compared to untreated urine (Fig. 2c). However, while previous studies have 
shown that CDME interferes with cystine crystal growth and results in crystals of distinctly 
different shape10, α-LA treatment did not alter the cystine hexagonal crystal habit 
(Supplementary Fig. 4). Further, synthetic α-LA had no detectable effect on cystine 
solubility, suggesting that α-LA did not directly interfere with cystine precipitation (Fig. 
2d). This result is consistent with the observation that exogenous α-LA is known to undergo 
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extensive metabolism in both mice and humans, including β-oxidation, sulfur methylation, 
sulfur oxidation, and glycine conjugation in mice, before being excreted into the urine19. It 
is likely that these α-LA-derived metabolic changes and/or metabolites in the urine are 
ultimately responsible for preventing cystine stone formation in Slc3a1-/- mice. Further 
investigation will be needed to identify the specific metabolite(s) of α-LA responsible for 
increasing cystine solubility, and how these α-LA-induced changes affect cystine 
crystallization.
We report here a new therapeutic application of α-LA treatment that protects against cystine 
stone formation in a mouse model of cystinuria. While α-LA has previously been implicated 
for its beneficial effects in promoting stress-activated signaling mechanisms, our data 
identifies a novel function of α-LA on that relies upon increasing urinary cystine solubility, 
likely via the excretion of downstream α-LA metabolites into the urine. This increase in 
cystine solubility is achieved without inducing changes to urinary pH, which predisposes to 
other types of stone formation (e.g. calcium phosphate)20. That α-LA is a widely available 
nutritional supplement with few adverse side effects13 makes it potentially advantageous 
over currently available medications and a particularly attractive candidate for assessment in 
individuals with cystinuria. These findings highlight a new avenue for treating and 
preventing cystine stone recurrence, and have implications for understanding treatment 
approaches for other types of urinary stone disease.
Online Methods
Animals
Homozygous Slc3a1-/- male mice (on a mixed C57Bl/6 and 129/SvJ background) were bred 
and maintained as previously described21. Specifically, Slc3a1-/- mice were generated by 
homologous recombination in embryonic stem (ES) cells. A 24 kb DNA fragment was 
isolated by screening a 129/SvJ genomic library. A targeting vector was constructed by 
replacing 5.7 kb of the wild-type sequence that included exon 1 with a 1.7 kb neomycin 
cassette under the control of a PGK1 promotor. The vector also included a 2.9 kb 5’ 
homology arm, a 5.6 kb 3’ homology arm, and a thymidine kinase sequence upstream of the 
5’ homology arm. Southern blotting with 5’ and 3’ screening probes located external to the 
homology arms were used to verify the difference in fragment size between the wild-type 
(24 kb) and knockout (20 kb) alleles. The targeting vector was linearized with the restriction 
enzyme AflII and then electroporated into 129/SvJ ES cells. Recombinant clones were 
identified using the 5’ and 3’ probes and the presence of the PGK-neo cassette in the 
knockout allele was confirmed using a neo probe. For each experiment, Slc3a1-/- littermate 
mice were randomly assigned to treatment or control groups. Wild-type (129X1/SvJ) and 
Nrf2-/- mice were purchased from Jackson laboratories, Nrf2-/- were bred to Slc3a1-/- mice 
to generate Slc3a1-/-; Nrf2-/- and Slc3a1-/-; Nrf2+/+ littermate controls.
α-lipoic acid was administered via 0.5%, 0.25%, or 0.1% (w/w) supplementation in the diet 
(Envigo); control mice were administered a non-supplemented equivalent diet. Tiopronin, N-
(2-mercaptopropionyl)glycine, was administered via daily oral gavage at 3.7 mg/day, the 
mouse dose equivalent of the tiopronin 1000 mg/day dose prescribed to patients, calculated 
according to the body surface area normalization method12. L-CDME was administered via 
Zee et al. Page 4
Nat Med. Author manuscript; available in PMC 2017 October 25.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
daily oral gavage at 2 mg/day, as was previously done8. Control mice for these experiments 
were administered water only as a vehicle control. Sulforaphane was administered via 
intraperitoneal injection three times per week at 25 mg/kg in PBS. Control mice were 
administered PBS only as a vehicle control.
24-hour food and water intake was measured using group-housed mice (3 to 4 mice per 
cage) in metabolic cages (Promethion). For urinary pH determination, urine from Slc3a1-/- 
mice was collected from voluntary expulsion and measured using a micro combination pH 
electrode (Lazar).
All experiments detailed here involving the use of animals were reviewed and approved by 
the Institutional Animal Care and Use Committees (IACUC) of the Buck Institute and 
Rutgers University.
Micro-computed tomography (μCT)
Stone growth rate was calculated from weekly measurements taken during a period of 6 
weeks. As Slc3a1-/- mice are susceptible to mortality, measurements from time points 
immediately prior to any deaths were excluded from analysis14,22. Mice were anesthetized 
and scanned weekly using Skyscan 1176 microcomputed tomography (μCT) scanner 
(Bruker Corp, Billerica, MA). The Skyscan reconstruction program NRecon was used for 
image reconstruction, and bladder stone volume was quantified using the Bruker CT-
Analyzer (CTAn, Version 1.14) program. 3-D image models were created using CTAn and 
Bruker CT-Volume (CTVol, Version 2.2).
Kidney histology
Kidney tissues were fixed in formalin and embedded in paraffin. 7 μM sections were then 
stained with Hematoxylin and Eosin.
Cystine determination
Urine from Slc3a1-/- mice collected from voluntary expulsion, and internal standard DL-
cystine (3,3,3’,3’-D4, Cambridge Isotope Laboratories) was added immediately to the 
samples. Urine samples were then sored at -80°C prior to cystine estimation. Urinary cystine 
was measured using the EZ-FAAST® kit from Phenomenex, Inc. (Torrance, CA) coupled 
with LC-MS/MS, following vendor-provided directions. Creatinine levels were determined 
using an assay kit according to manufacturer’s instructions (Cayman Chemical).
Cystine precipitation assay
100 mL of 4 mM supersaturated L-cystine solution was prepared by heating a cystine 
suspension in water, under reflux at 100°C for 20 min with continuous stirring to completely 
dissolve L-cystine, as previously described10. 400 μL of this supersaturated L-cystine 
solution was added to borosilicate glass tubes (3 technical replicates per condition per 
experiment) containing 100 μL of water (blank), synthetic compounds (at least 3 
independent experiments performed), or mouse urine (at least 2 independent experiments 
performed) and vortexed briefly to homogenize the contents. The solutions were 
subsequently incubated at 4°C for 3 days to allow cystine precipitation. At the end of the 
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incubation period, the tubes were centrifuged at 4000 rpm for 20 min and the supernatant 
discarded. The remaining cystine precipitate was dissolved in 3.6 mL of 25 μM d4-cystine 
(internal standard) solution and 2 μL injected for LC-MS/MS analysis. Mouse urine samples 
were obtained from 24 h urine collections from 129X1/SvJ male mice treated with or 
without 0.5% α-lipoic acid (Tecniplast).
Liquid chromatography tandem mass spectrometry (LC-MS/MS)
Liquid chromatography (LC) was performed using a Shimadzu UFLC prominence system 
fitted with following modules: CBM-20A (Communication bus module), DGU-A3 
(degasser), two LC-20AD (liquid chromatograph, binary pump), SIL-20AC HT (auto 
sampler) and connected to a Phenomenex Luna® NH2 column (2 × 150 mm, 3 μm, 100 Å). 
Mass spectrometry (MS) was performed using a 4000 QTRAP® LC-MS/MS mass 
spectrometer from AB SCIEX fitted with a Turbo V™ ion source. AB SCiex’s Analyst® 
v1.6.1 was used for all forms of data acquisition, development of LC method, and 
optimization of analyte-specific MRM (multiple reaction monitoring) transitions. AB 
SCiex’s Peakview® v2.1 and Skyline® v3.523 was used for LC-MS/MS data analysis.
Optimization of cystine- and d4-cystine-specific multiple reaction monitoring (MRM) 
transitions, such as determination of suitable precursor and product ions and optimal MS 
parameters for each transition (Q1, precursor → Q3, product) were achieved by isocratic 
flow injection of the 10 μM solution for each compounds. The most intense (Q1→ Q3) 
transition was used as quantifier, whereas the next best transition was used as qualifier for 
each compound (see table below). For LC separation, a solvent gradient of 95% of 20 mM 
ammonium acetate/20 mM ammonium hydroxide (pH~9.5) in water and 5% acetonitrile 
(aqueous) - acetonitrile (organic) was used with 0.4 mL/min flow rate, starting with an 
acetonitrile content of 50% for 1.5 min, which was decreased to 2% over 3.5 min and held at 
2% for 1.5 min. The LC column was subsequently reconstituted to its initial condition 
(organic content of 50%) over the next 1 min and re-equilibrated for 4 min. For cystine 
estimation (retention time = 4.9 min), the mass spectrometer was operated in positive ion 
mode. Source conditions were as follows: curtain gas (CUR) 20, nebulizer gas (GS1) 60, 
auxiliary gas (GS2) 50, ionspray voltage (IS) 4500 V, and source temperature (TEM) 450°C. 
Quantification of cystine was based on integration of corresponding LC-MS/MS-specific 
quantifier peaks (peak areas) and the corresponding quantifier peak area for d4-cystine.
Statistical analyses
Littermate mice were randomly assigned to treatment or control groups for each experiment. 
Investigators were not blinded to group allocation. Most experiments included a control-only 
period before randomization to ensure mice would survive long enough for study. Those that 
did not survive to randomization were removed from the study (n = 7 mice). Means and 
standard errors were calculated in each treatment and control group. Two-sided Student’s t-
tests were used to compare differences in mean stone volume at single time points, urinary 
cystine levels, and relative cystine precipitate. Experiments involving multiple t-tests were 
adjusted for multiple comparisons using the Benjamini-Hochberg-Yekutieli procedure, 
which controls for false discovery rate among correlated tests24. Linear mixed regression 
models were used to assess the associations between treatment groups and stone growth over 
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time. Sample size calculations were conducted assuming linear mixed regression models 
with six time points during each treatment period and stone growth of 1 mm3 per day in the 
control group. Assuming stone growth of 0.6 mm3 per day in the treatment group, at least n 
= 4 mice were required in each group to have at least 80% power to detect differences across 
treatment and control groups. Assuming stone growth of 0.7 mm3 per day, n = 6 mice in 
each group were needed.
Given the approximately linear increase in stone volume, time was used as a continuous 
variable in linear mixed regression models. An interaction term between time and treatment 
group was included to test for differences in mean stone growth across treatment groups. For 
experiments with more than two treatment groups, interaction terms were first jointly tested 
across all treatment groups. If the overall test indicated a significant interaction, differences 
between each pair of treatment groups were tested. Random intercepts for each mouse were 
included in regression models to account for the correlated, repeated stone volume measures 
within mice. For experiments in which mice were switched from one diet to another, linear 
splines were included in models with knots at the times of switch to allow for different stone 
growth rates while on each diet. For experiments in which mice were randomized to α-lipoic 
acid treatments or control after a control-only period, mean stone growth rates were adjusted 
for baseline stone growth, defined by the mean stone growth rate in each mouse prior to 
randomization. A three-way interaction between mouse group, treatment group, and time 
was used in the regression model to test whether Nrf2-/- modified the effect of α-lipoic acid 
compared to treatment. Two-sided tests were used in all models.
Stone volumes over time were plotted prior to modeling to ensure volume increased 
approximately linearly in each experiment and the continuous form of time in models was 
appropriate. Random intercepts and residuals estimated from models were plotted using 
histograms and quantile-quantile plots to check for normality. There was no evidence of any 
violations of these model assumptions. A Poisson regression model was used to compare the 
counts of stones between the control and α-lipoic acid groups. Model assumptions, 
including overdispersion and zero-inflation, were checked and there was no evidence of 
assumption violations. All statistical analyses were conducted using R 3.2.3 software (R 
Foundation for Statistical Computing, Vienna, Austria).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
α-Lipoic acid inhibits cystine stone formation in the Slc3a1-/- mouse model of cystinuria. (a) 
In vivo bladder stone growth in a representative Slc3a1-/- male mouse (n = 24), quantified by 
μCT analysis. (b) Stone growth rate in stone-forming Slc3a1-/- mice treated with α-lipoic 
acid (0.5%, w/w supplementation in the diet) (n = 4) compared to control, untreated mice (n 
= 5). Statistical differences in stone volume growth rate relative to the control were tested 
using a linear mixed regression model. (c) Stone volume in Slc3a1-/- mice reared on α-lipoic 
acid supplemented diet (n = 8) compared to untreated control mice (n = 7) (Left). Statistical 
differences in stone volume between α-lipoic acid treatment and control at each point were 
determined by Student’s t-tests, after adjusting for multiple comparisons (see Online 
Methods). (Right) Representative radiograph images (n = 361 μCT scans) of the pelvic 
region of control mice and α-lipoic acid-treated mice on day 115 of treatment. Results are 
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representative of three independent experiments. Scale bar, 1 cm. (d) Stone growth rate 
evaluated by weekly μCT for 6 weeks of pre-treatment, α-lipoic acid treatment, and post-
treatment periods in Slc3a1-/- mice (n = 9). Statistical differences in stone volume growth 
rate between treatment periods were tested using a linear mixed regression model with linear 
spline. (e) Stone growth rate in Slc3a1-/- mice upon different doses of α-lipoic acid 
administration (control, n = 5; 0.1% LA, n = 7; 0.25% LA, n = 7 ; 0.5% LA, n = 5). 
Statistical differences in stone volume growth rate were tested using a linear mixed 
regression model. Error bars represent mean ± s.e.m. Data are plotted for individual mice; 
*P < 0.05, **P < 0.01, ***P < 0.001. ns, not significant.
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Figure 2. 
α-Lipoic acid increases cystine solubility in the urine environment. (a) Urinary cystine 
concentration from wild-type (n = 2), control Slc3a1-/- (n = 4), and α-lipoic acid-treated 
Slc3a1-/- (n = 5) mice. Values are normalized to creatinine measurements. Error bars 
represent mean ± s.e.m. Statistical differences in urinary cystine concentration were 
determined by Student’s t-test. (b) Stone growth rates in Slc3a1-/- mice (control, n = 8; 
treated, n = 10) and Slc3a1-/-;Nrf2-/- (control, n = 10; treated, n = 10) treated with α-lipoic 
acid. Data are plotted for individual mice, error bars represent mean ± s.e.m, and statistical 
differences across mouse groups in the effects of α-lipoic acid compared to control were 
tested using a linear mixed regression model. (c) Relative yield of L-cystine precipitation 
obtained after crystallization for 3 days in the presence of urine from untreated- and α-lipoic 
acid-treated wild-type mice compared to blank (water). Statistical differences were 
determined by Student’s t-test. The error bars represent mean ± s.d. based on three 
measurements. (d) Relative yield of L-cystine precipitation obtained after crystallization for 
3 days in the presence of α-lipoic acid (500μM) and L-cystine dimethyl ester (CDME, 
500μM), a positive control10 compared to blank (water). Statistical differences were 
determined by student’s t-test. The error bars represent mean ± s.d. based on three 
measurements. *P < 0.05, **P < 0.01, ***P < 0.001. ns, not significant.
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